RECORDATI 341 0 Kommentare BOARD APPROVES THE 2017 ACCOUNTS. SALES € 1,288.1 MILLION (+11.6%), OPERATING INCOME € 406.5 MILLION (+24.1%) AND NET INCOME € 288.8 MILLION (+21.6%). 2017 DIVIDEND € 0.85 (+21.4%)

Consolidated revenues € 1,288.1 million, +11.6%.
EBITDA ⁽¹⁾ € 454.7 million, +22.5%

Operating income € 406.5 million, +24.1%.

Net income € 288.8 million, +21.6%.

Net financial position ⁽²⁾: net debt of € 381.8 million.

Dividend for 2017 € 0.85 per share, of which € 0.42 already paid.

Annual Meeting of Shareholders convened for 18 April 2018, the sole convocation date.

Milan, 15 March 2018 - Recordati's Board of Directors approved the consolidated financial statements for the year 2017 as well as Recordati S.p.A.'s accounts and the corporate governance and ownership report as required by art. 123bis of the Consolidated Law on Financial Intermediation. The financial statements at and for the year ended 31 December 2017 and the aforesaid report will be available as from today 15 March 2018 at the company's head office and published on the company's website www.recordati.com and can also be viewed on the authorized storage system 1Info (www.1Info.it). The reports issued by the independent and by the statutory Auditors will be made available, within the terms of the law, in the same manner. The Board of Directors also approved the consolidated non financial information disclosure pursuant to Legislative Decree n. 254 dated 30 December 2016 which will be made available in the same manner.

Financial highlights

Consolidated revenues in 2017 are € 1,288.1 million, up by 11.6% compared to the preceding year. International sales grow by 12.4%.
EBITDA ⁽¹⁾, at 35.3% of sales, is € 454.7 million, an increase of 22.5% over the preceding year.
Operating income, at 31.6% of sales, is € 406.5 million, an increase of 24.1%.
Net income, at 22.4% of sales, is € 288.8 million, an increase of 21.6% over 2016.
Net financial position ⁽²⁾ at 31 December 2017 shows a net debt of € 381.8 million compared to net debt of € 198.8 million at 31 December 2016. During the period dividends were distributed, the acquisition of the marketing rights to the metoprolol based products from AstraZeneca was concluded and three Bayer Consumer Health products were acquired for an overall disbursement of € 456.5 million.